Internal Medicine IV

The Department of Internal Medicine IV provides medical care for patients suffering from renal disease and hypertension. The department, which has been in existence for many years, is also home to the only university chair in nephrology in Saarland and Rhineland Palatinate. Equipped with advanced medical technology, our department is able to provide the highest quality diagnostic and therapeutic interventions for patients with renal and hypertensive disorders. We also run risk-factor consultation sessions to teach preventive strategies concerning in particular: hypertension, fat metabolism, excess weight, sedentary lifestyles, stress and medication. Patients found to be already suffering from advanced renal insufficiency will receive expert advice and, where necessary, will undergo kidney replacement therapy such as haemodialysis, peritoneal dialysis or kidney transplantation. Transplantations are carried out in cooperation with the Department of Urology. Besides receiving professional inpatient treatment, patients are also supervised in our numerous specialist consulting sessions. The research carried out at the department is mainly focused on cardiovascular complications in cases of chronic renal insufficiency, and infection monitoring in immunosuppressed patients. Our research programmes are supported by the German Research Council (DFG), the Else Kröner-Fresenius Foundation, the German José Carreras Leukaemia Foundation and other project-specific funds.

Seiler S, Colbus SM, Lucisano G, Rogacev KS, Gerhart MK, Ziegler M, Fliser D, Heine GH.

Ultrasound renal resistive index is not an organ-specific predictor of allograft outcome.

Nephrology Dialysis Transplantation 2012; doi: 10.1093/ndt/gfr805. Impact factor: 3.6

Hodapp T^*, Sester U^*, Mack U, Singh M, Meier T, Wiech E, Fisch P, Ehl S, Sester M.

Massive monoclonal expansion of CD4 T-cells specific for a M. tuberculosis ESAT-6 peptide.

Eur Respir J 2012 Jan 20. Impact factor: 5.9. Abstract

Rogacev KS, Bittenbring JT, Fliser D.

Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.

N Engl J Med 2011 Nov 3;365(18):1745-6; author reply 6-7. Impact factor: 53.5. Abstract